Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:747 2006
DOI: 10.2337/diacare.29.03.06.dc05-2270
© 2006 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strowig, S. M.
Right arrow Articles by Raskin, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Strowig, S. M.
Right arrow Articles by Raskin, P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Letters: Comments and Responses

The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes

Response to Orchard

Suzanne M. Strowig, MSN, RN and Philip Raskin, MD

1 From the Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas

Address correspondence to Suzanne M. Strowig, MSN, RN, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-8858. E-mail: suzanne.strowig{at}utsouthwestern.edu

Our report (1) on the effect of rosiglitazone on overweight subjects with type 1 diabetes showed that rosigolitazone-treated subjects with a BMI ≥30 kg/m2 experienced significantly greater improvements in HbA1c (A1C) levels than those with a BMI <30 kg/m2 (–1.4 vs. –0.4%, P = 0.032). In addition, regression analysis showed that BMI, total daily insulin dose, and total, LDL, and HDL cholesterol levels were predictors of improvement in A1C (1). In his letter (2), Orchard raises the intriguing possibility that an estimate of insulin sensitivity (eGDR), which is based on waist-to-hip ratio, hypertension status, and A1C (3), could be an identifier of type 1 diabetic individuals who might benefit from thiazolidinedione therapy. We calculated eGDR in our subjects and found that in the rosiglitazone-treated subjects, eGDR was significantly related to change in A1C level (P = 0.003, r = 0.575). No such relationship was found in the placebo-treated subjects. However, a regression analysis incorporating BMI; total daily insulin dose; total, LDL, and HDL cholesterol; and eGDR showed that eGDR was not a significant predictor of improvement in A1C (P = 0.155) in the rosiglitazone-treated subjects.

Waist-to-hip ratios were the same in both the rosiglitazone and placebo groups at baseline (0.91 ± 0.06) and at the end of the study (0.93 ± 0.06), which is consistent with the observation that weight gain with thiazolidinediones is mainly peripheral rather than central. Orchard (2) noted that blood pressure but not lipids improved in our rosiglitazone-treated type 1 diabetic subjects. This result was somewhat surprising since we had observed the opposite results in our studies of troglitazone in combination with insulin in type 2 diabetic subjects (4,5). It is important to keep in mind that these studies were not designed to evaluate the effect of thiazolidinedione therapy on blood pressure; all of our subjects were treated with antihypertensive medications in an effort to normalize blood pressure levels. In addition, baseline blood pressure and history of hypertension were not related to change in A1C and were not significant predictors of improvement in A1C level in our rosiglitazone-treated type 1 diabetic subjects. Triglyceride levels also were not related to change in A1C. On the other hand, markers of insulin resistance in the type 1 diabetic subjects, such as BMI, total daily insulin dose, and cholesterol levels, were related to improvement in glycemic control when rosiglitazone treatment was used. Therefore, we do not believe that we can draw any firm conclusions from our data about the relative linkage of blood pressure versus lipid levels to insulin resistance.

References

  1. Strowig SM, Raskin P: The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 28:1562–1567, 2005[Abstract/Free Full Text]
  2. Orchard TJ: The effect of rosiglitazone on overweight subjects with type 1 diabetes (Letter). Diabetes Care 29:746–747, 2006[Free Full Text]
  3. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ: Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632, 2000[Abstract]
  4. Strowig SM, Avilés-Santa ML, Raskin P: Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care 25:1691–1698, 2002[Abstract/Free Full Text]
  5. Strowig SM, Avilés-Santa ML, Raskin P: Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27:1577–1583, 2004[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strowig, S. M.
Right arrow Articles by Raskin, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Strowig, S. M.
Right arrow Articles by Raskin, P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum